Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reaching the "Hard-to-Reach" Sexual and Gender Diverse Communities for Population-Based Research in Cancer Prevention and Control: Methods for Online Survey Data Collection and Management.
Myers KJ, Jaffe T, Kanda DA, Pankratz VS, Tawfik B, Wu E, McClain ME, Mishra SI, Kano M, Madhivanan P, Adsul P. Myers KJ, et al. Among authors: tawfik b. Front Oncol. 2022 Jun 8;12:841951. doi: 10.3389/fonc.2022.841951. eCollection 2022. Front Oncol. 2022. PMID: 35756657 Free PMC article.
Developing a survivorship care plan (SCP) delivery process for patients and primary care providers serving poor, rural, and minority patients with cancer.
Tawfik B, Jaffe SA, Mohler L, Oomen-Hajagos J, Gil IS, Chamberlain R, Gagnon S, Kano M, Gundelach A, Ryan SR, Abernathy J, Wiggins C, Sussman A, Dayao Z. Tawfik B, et al. Support Care Cancer. 2021 Sep;29(9):5021-5028. doi: 10.1007/s00520-021-06043-w. Epub 2021 Feb 15. Support Care Cancer. 2021. PMID: 33587174 Free PMC article.
Patient, provider, and nurse preferences of patient reported outcomes (PRO) and side effect management during cancer treatment of underrepresented racial and ethnic minority groups, rural and economically disadvantaged patients: a mixed methods study.
Tawfik B, Burgess E, Kosich M, Jaffe SA, Guest DD, Brown-Glaberman U, Pankratz VS, Sussman A. Tawfik B, et al. Cancer Causes Control. 2022 Sep;33(9):1193-1205. doi: 10.1007/s10552-022-01605-7. Epub 2022 Jul 13. Cancer Causes Control. 2022. PMID: 35829828 Free PMC article.
A Remotely Delivered Light-Intensity Physical Activity Intervention for Older Cancer Survivors: Protocol for a Feasibility Randomized Controlled Trial.
Blair CK, Brown-Glaberman U, Walters ST, Pestak C, Boyce T, Barriga L, Burgess E, Tawfik B, Killough C, Kinney AY, Demark-Wahnefried W, Meisner AL, Wiggins CL, Pankratz VS, Davis S. Blair CK, et al. Among authors: tawfik b. JMIR Res Protoc. 2024 Dec 13;13:e59504. doi: 10.2196/59504. JMIR Res Protoc. 2024. PMID: 39671575 Free PMC article.
Pharmacist-Driven Oral Oncolytic Medication Education and Consent.
Bowles H, Tawfik B, Abernathy J, Lauer R, Hashemi N, Dayao Z. Bowles H, et al. Among authors: tawfik b. JCO Oncol Pract. 2020 Oct;16(10):e1209-e1215. doi: 10.1200/JOP.19.00418. Epub 2020 May 27. JCO Oncol Pract. 2020. PMID: 32459565
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Mayer IA, et al. Among authors: tawfik b. J Clin Oncol. 2021 Aug 10;39(23):2539-2551. doi: 10.1200/JCO.21.00976. Epub 2021 Jun 6. J Clin Oncol. 2021. PMID: 34092112 Free PMC article. Clinical Trial.
65 results